



Pure Bioscience completes planned reincorporation

Friday, March 25, 2011

Pure Bioscience (Nasdaq: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced that effective March 24, it completed its reincorporation in the state of Delaware by merging into a wholly-owned Delaware subsidiary.

The reincorporation was approved by the shareholders of Pure at the annual meeting of shareholders held on Jan. 19, 2011, and adjourned and continued on Feb. 10.

The company's name has changed from Pure Bioscience to Pure Bioscience Inc., and its CUSIP number has changed to 74621T 100. The company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "PURE."

In the merger, each outstanding share of Pure's common stock was converted into one share of common stock of the surviving Delaware corporation. Following the reincorporation, holders of common stock of Pure continue to own the same number of shares of common stock in the surviving Delaware corporation as they owned prior to the reincorporation.

Shareholders of Pure do not need to exchange their stock certificates for stock certificates of the Delaware corporation. The reincorporation did not result in any change in Pure's Nasdaq listing, business, management, directors, assets, physical location, operations or liabilities. Additionally, in connection with the reincorporation, the authorized number of shares of common stock of the company has increased to 100 million.